New Jersey Acting Attorney General Jennifer Davenport, alongside 42 states and territories, filed a multistate complaint against Novartis AG and its subsidiaries Sandoz AG and Sandoz Group AG alleging a conspiracy to fix prices, allocate markets, and rig bids for 31 generic drugs, inflating costs for consumers and public healthcare programs. The complaint also alleges Novartis fraudulently spun off Sandoz to shield itself from liability for prior antitrust violations. This action builds on evidence from three previous multistate generic drug price-fixing complaints.
Entity
Novartis AG, Sandoz AG, Sandoz Group AG
Industry
HealthcareOfficial Press Release
https://www.njoag.gov/acting-ag-davenport-files-multistate-complaint-against-novartis-and-sandoz-alleging-prescription-drug-price-fixing/
2026 0203 Novartis Complaint Bates Stamped
http://www.njoag.gov/wp-content/uploads/2026/02/2026-0203_Novartis-Complaint-Bates-Stamped.pdf
GDMS First Amended Complaint
https://nj.gov/oag/newsreleases17/GDMS-First-Amended-Complaint.pdf
Complaint
https://www.nj.gov/oag/newsreleases19/Complaint.pdf
New Jersey Attorney General Enforcement Page
https://www.njoag.gov/about/divisions-and-offices/division-of-consumer-affairs/
"against Novartis AG and its generic subsidiaries Sandoz AG and Sandoz Group AG"
"For Immediate Release: February 3, 2026"
"New Jersey filed a multistate complaint"
"multistate complaint with 42 states and territories"
"federal and state antitrust law"
"New Jersey Consumer Fraud Act"
A multistate coalition co-led by New Jersey won a federal court order rejecting the Trump Administration’s decision not to request funding for the CFPB. The order struck down that decision and directed the Administration to follow the law and fund the agency; no monetary penalty or privacy violation is described.
New Jersey’s Attorney General and Division of Consumer Affairs alerted the public that three synthetic kratom-related compounds became illegal to possess or sell in the state under a temporary federal scheduling order. The release describes a controlled-substance alert, not a privacy enforcement action, and identifies no company, privacy violation, or monetary penalty.
$2.3M
Laboratory Corporation of America Holdings agreed to pay $2,287,455 to participating states and strengthen its security and vendor-management practices following an investigation into the 2019 breach at its debt-collection vendor, AMCA. The breach potentially exposed information of more than 27.5 million people nationwide, including sensitive information belonging to approximately 10.2 million LabCorp patients.
$694.0M
New Jersey's Attorney General and Division of Consumer Affairs, along with 41 Attorneys General, reached a $694 million settlement with subprime auto lender Credit Acceptance Corporation over allegations it originated unaffordable loans its own systems predicted borrowers could not repay, employed aggressive debt-collection tactics, and failed to prevent deceptive vehicle-service contract and GAP product 'packing' by dealers. The multistate settlement stepped in after the CFPB permanently dropped its 2023 enforcement action against CAC in 2025. CAC will provide $60 million in cash restitution, $634 million in debt relief, an additional $15 million to the states, and implement injunctive lending reforms including loan off ramps, pre-loan disclosures, add-on packing safeguards, and a seven-year vehicle price cap. Note: this is a consumer-protection lending enforcement action, not a privacy matter; violation categories are best-fit mappings from the available taxonomy.
$650K
The New Jersey Attorney General and Division of Consumer Affairs announced that Match Group, Inc. will pay $650,000 and change its business practices to settle allegations that it misrepresented or failed to disclose its criminal background screening policies and practices to New Jersey users, violating the New Jersey Consumer Fraud Act and the Internet Dating Safety Act. Under a Consent Order, Match must accurately represent its screening policies, notify existing New Jersey members of updated disclosures within 150 days, and post clear and conspicuous disclosures and safety notifications about the limitations of criminal background screenings.
$96.5M
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.